

<i>Tissue Microarray Availability Section</i>	<i>Description</i>
2.1	Tissue Sites Summary
2.2	Tissue Microarray and DNA Core Availability by Tissue Site
2.3	Biospecimen Availability by Tissue Site
2.4	PLCO Study Demographics by Tissue Site
2.5	Tissue Site Cancer and Adenoma Characteristics

Table 2.1: Tissue Sites Summary

<i>Tissue Site</i>	<i>Initial Selection and Tissue Information</i>
Prostate	Prostate tissue was selected in Fall 2007. Subjects with a prostatectomy, and who were in CGEMS or had blood/buccal cell available were selected. One-half of the eligible cases with buccal cell, not in CGEMS, were selected. The CGEMS cases' prostate cores were preferentially selected; TMA blocks have been organized into CGEMS vs non-CGEMS boxes. A separate tissue selection for subjects from the PCP study was later conducted. Some subjects from the PCP study are unlinkable to their corresponding cores.
Lung	Lung tissue was selected in Fall 2009. Subjects targeted for tissue were: never smokers, interval cancers, small aggressive lung cancers, and African Americans. Subjects were identified for selection if they had evidence of a biopsy, or surgery obtaining tissue.
Colorectal	Colon tissue was selected in Spring 2006. All eligible subjects were targeted for selection, including a small number of multiple-primary cases. The cases are split into pre-treatment and post-treatment tissue. An additional selection was done in Fall 2013.
Ovarian	Ovary tissue was selected in two waves. The first set of ovary tissue was selected in Summer 2006 and the second in Fall 2010. Subjects with either Path T or an oophorectomy were identified for selection. Cancer cases included invasive ovarian, fallopian tube, and primary peritoneals.
Adenoma	Adenoma Tissue was selected in Spring 2007. Selection groups included: ACF subjects, African Americans, and participants with recurrent adenomas, incident adenomas, and prevalent adenomas; preference was taken in selecting non-prevalent adenomas. Only 300 subjects were taken from each study center for adenoma tissue. Only large adenomas were selected because of concerns that there would not be enough material to array.
Breast	Breast tissue was selected in Fall 2010. Tissue was preferentially selected if the participant was included in the Breast CGEMS study. Invasive cancers were also preferentially selected over in-situ cases. Only tumors size 0.5cm or greater were selected. An additional selection consisting of exclusively in-situs was done in Fall 2012 using the same criteria as the Fall 2010 selection.
Male Breast	Male Breast tissue was selected in Fall 2010. All 27 cases were selected for tissue extraction, including cases where the cancer was reported but not yet confirmed. Unlike female breast cancer, tumor size was not taken into account in selection.
Bladder	Bladder tissue was selected in Fall 2012. All available invasive and in situ cases of specific morphologies were selected.
LSS	Lung tissue is available for subjects from the Lung Screening Study (LSS) group of the National Lung Screening Trial (NLST).

Table 2.2.1: Tissue Microarray and Tumor DNA Availability by Tissue Site

	<i>Prostate</i>	<i>Lung</i>	<i>Colorectal</i>	<i>Ovarian</i>	<i>Adenoma</i>	<i>Breast</i>	<i>Male Breast</i>	<i>Bladder</i>	<i>LSS</i>
<i>Selected by IMS</i>	1652	1030	1398	321	2468	1852	27	901	.
<i>With Donor Blocks Received</i>	1103	502	775	228	871	1025	18	293	463
<i>With TMA Cores</i>	1091	434	673	212	658	801	17	201	438
<i>With TMA Tumor Cores</i>	956	434	662	211	658	801	17	201	437
<i>With Tumor DNA</i>	700	433	418	211	197	770	17	159	434
<i>With TMA Cores and Tumor DNA</i>	700	433	417	211	197	769	17	156	434
<i>With TMA Cores or Tumor DNA</i>	1091	434	674	212	658	802	17	204	438
<i>With H&E Slides</i>	1095	492	749	227	768	1012	18	285	449
<i>Total H&E Slides</i>	2999	1521	2777	872	1103	2909	56	483	1252
<i>With Pathology Images</i>	1095	492	749	227	768	1012	18	285	452
<i>Total Pathology Images</i>	2999	1521	2777	874	1103	3305	56	483	1252

Table 2.2.2: Tissue Microarray and Tumor DNA Availability by Tissue Site and Phase for Sites with Multiple Selections

	<i>Prostate Non CGEMS</i>	<i>Prostate CGEMS</i>	<i>Prostate PCP</i>	<i>Colorectal Pre TX</i>	<i>Colorectal Post TX</i>	<i>Colorectal Second Selection</i>	<i>Ovarian Selection 1</i>	<i>Ovarian Selection 2</i>	<i>Breast Selection 1</i>	<i>Breast Selection 2</i>	<i>Breast In Situ selection</i>
<i>Selected by IMS</i>	634	418	51	533	20	222	136	92	547	383	95
<i>With Donor Blocks Received</i>	634	418	51	533	20	222	136	92	547	383	95
<i>With TMA Cores</i>	634	418	39	486	12	175	130	82	473	328	0
<i>With TMA Tumor Cores</i>	542	375	39	486	12	164	129	82	473	328	0
<i>With Tumor DNA</i>	365	335	0	256	6	156	129	82	452	317	1
<i>With TMA Cores and Tumor DNA</i>	365	335	0	255	6	156	129	82	452	317	0
<i>With TMA Cores or Tumor DNA</i>	634	418	39	487	12	175	130	82	473	328	1
<i>With H&E Slides</i>	633	418	44	521	20	208	136	91	538	380	94
<i>Total H&E Slides</i>	1731	1145	123	2165	92	520	532	340	1516	1149	244
<i>With Pathology Images</i>	633	418	44	521	20	208	136	91	538	380	94
<i>Total Pathology Images</i>	1731	1145	123	2165	92	520	534	340	1516	1149	640

Table 2.3: Biospecimen Availability by Tissue Site

	<i>Prostate TMA</i>	<i>Prostate DNA</i>	<i>Lung TMA</i>	<i>Lung DNA</i>	<i>Colorectal TMA</i>	<i>Colorectal DNA</i>	<i>Ovarian TMA</i>	<i>Ovarian DNA</i>	<i>Adenoma TMA</i>	<i>Adenoma DNA</i>	<i>Breast TMA</i>	<i>Breast DNA</i>	<i>Male Breast TMA</i>	<i>Male Breast DNA</i>	<i>Bladder TMA</i>	<i>Bladder DNA</i>
<i>All</i>	1091	700	434	433	673	418	212	211	658	197	801	770	17	17	201	159
<i>RBC (Pre-DX)</i>	826	546	243	242	290	186	106	105	563	175	577	551	9	9	92	76
<i>Serum (Pre-DX)</i>	793	518	235	234	271	177	105	104	526	156	559	533	9	9	95	79
<i>Plasma (Pre-DX)</i>	192	109	67	67	119	83	41	41	95	25	202	188	7	7	53	45
<i>EDTA Plasma (Pre-DX)</i>	334	190	129	128	135	97	65	64	118	29	321	303	8	8	77	65
<i>Heparin Plasma (Pre-DX)</i>	775	507	160	159	265	173	104	103	516	151	546	520	9	9	92	76
<i>Serum + DNA (Pre-DX)</i>	779	512	223	222	249	167	103	102	512	151	543	517	9	9	91	75
<i>Serum (Post-DX)</i>	465	323	87	87	117	60	31	30	393	124	252	242	2	2	15	14
<i>Plasma (Post-DX)</i>	298	210	55	55	80	40	18	17	280	85	173	167	1	1	7	6
<i>EDTA Plasma (Post-DX)</i>	479	332	93	93	116	61	32	31	374	119	261	249	2	2	15	12
<i>Heparin Plasma (Post-DX)</i>	318	234	61	61	83	43	20	20	331	104	128	122	1	1	8	5
<i>Serum + DNA (Post-DX)</i>	464	323	85	85	111	58	30	29	384	120	251	241	2	2	15	14
<i>Serum (Pre-DX & Post-DX)</i>	454	315	87	87	105	55	28	27	385	120	247	237	2	2	15	14
<i>Any DNA</i>	1051	682	294	293	519	349	179	178	555	172	744	714	10	10	179	142
<i>In PLCO Total GWAS</i>	1027	661	348	347	553	341	165	164	549	169	685	658	12	12	164	131

Table is based on selected subjects with either TMA or tumor DNA available.

Table 2.4: PLCO Study Demographics by Tissue Site

	<i>Prostate Selected</i>	<i>Prostate TMA or DNA</i>	<i>Lung Selected</i>	<i>Lung TMA or DNA</i>	<i>Colorectal Selected</i>	<i>Colorectal TMA or DNA</i>	<i>Ovarian Selected</i>	<i>Ovarian TMA or DNA</i>	<i>Adenoma Selected</i>	<i>Adenoma TMA or DNA</i>	<i>Breast Selected</i>	<i>Breast TMA or DNA</i>	<i>Male Breast Selected</i>	<i>Male Breast TMA or DNA</i>	<i>Bladder Selected</i>	<i>Bladder TMA or DNA</i>
<i>All</i>	1652	1091	1030	434	1398	674	321	212	2468	658	1852	802	27	17	901	204
<i>Randomization Group</i>	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
<i>Control</i>	394	239	402	173	691	341	122	88	96	36	590	201	10	6	432	94
<i>Intervention</i>	1258	852	628	261	707	333	199	124	2372	622	1262	601	17	11	469	110
<i>Gender</i>	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
<i>Female</i>	.	.	453	185	599	285	321	212	811	210	1852	802	.	.	161	47
<i>Male</i>	1652	1091	577	249	799	389	.	.	1657	448	.	.	27	17	740	157
<i>Race</i>	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
<i>White, Non-Hispanic</i>	1488	993	882	389	1238	598	295	192	2203	556	1647	715	23	14	858	192
<i>Black, Non-Hispanic</i>	103	56	94	22	72	34	9	5	214	80	107	57	2	1	15	2
<i>Hispanic</i>	26	19	12	1	19	10	4	4	24	8	22	6	.	.	11	1
<i>Asian</i>	26	15	23	10	54	23	7	7	21	11	50	14	.	.	13	8
<i>Pacific Islander</i>	6	6	1	.	4	2	.	.	.	.	10	3	.	.	3	1
<i>American Indian</i>	3	2	.	.	3	2	.	.	3	2	3	.	.	.	1	.
<i>Missing</i>	.	.	18	12	8	5	6	4	3	1	13	7	2	2	.	.
<i>Study Center</i>	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
<i>University of Colorado</i>	166	117	53	18	111	72	25	20	213	77	179	75	4	3	87	21
<i>Georgetown University</i>	62	35	61	19	58	14	23	15	158	66	119	35	2	1	69	11
<i>Pacific Health Research and Education In</i>	27	17	43	16	80	39	9	8	11	4	66	19	5	4	36	17
<i>Henry Ford Health System</i>	197	122	143	50	209	89	42	31	317	87	269	115	1	1	135	26
<i>University of Minnesota</i>	444	332	206	122	246	114	60	41	456	93	294	175	4	2	204	40
<i>Washington University in St Louis</i>	118	95	119	47	152	69	30	23	225	114	213	85	2	.	87	22
<i>University of Pittsburgh</i>	193	121	129	32	178	78	45	19	390	83	209	52	3	2	113	14
<i>University of Utah</i>	173	101	70	19	130	55	41	24	225	73	191	68	3	1	59	12
<i>Marshfield Clinic Research Foundation</i>	225	133	139	90	189	135	33	26	334	37	205	118	2	2	111	41
<i>University of Alabama at Birmingham</i>	47	18	67	21	45	9	13	5	139	24	107	60	1	1	.	.
<i>Fiscal Year Of Randomization</i>	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
<i>1994</i>	143	76	57	23	114	54	15	11	177	37	113	40	2	2	86	16
<i>1995</i>	380	233	224	101	300	151	58	42	431	117	245	107	3	1	233	45
<i>1996</i>	349	216	182	77	251	132	60	40	553	156	340	161	8	4	165	49
<i>1997</i>	297	221	144	57	221	94	57	38	454	134	317	140	4	2	146	33
<i>1998</i>	178	124	145	62	168	91	54	36	296	73	287	120	2	.	104	20
<i>1999</i>	165	118	151	62	198	91	48	26	329	82	294	113	8	8	106	29
<i>2000</i>	116	90	97	45	112	51	23	15	175	47	215	99	.	.	50	11

Table 2.4: PLCO Study Demographics by Tissue Site

	<i>Prostate Selected</i>	<i>Prostate TMA or DNA</i>	<i>Lung Selected</i>	<i>Lung TMA or DNA</i>	<i>Colorectal Selected</i>	<i>Colorectal TMA or DNA</i>	<i>Ovarian Selected</i>	<i>Ovarian TMA or DNA</i>	<i>Adenoma Selected</i>	<i>Adenoma TMA or DNA</i>	<i>Breast Selected</i>	<i>Breast TMA or DNA</i>	<i>Male Breast Selected</i>	<i>Male Breast TMA or DNA</i>	<i>Bladder Selected</i>	<i>Bladder TMA or DNA</i>
2001	24	13	30	7	34	10	6	4	53	12	41	22	.	.	11	1
Cigarette Smoking Status	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Ambiguous	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
No Form	.	.	18	12	8	5	6	4	1	.	13	7	2	2	.	.
Not Answered	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
Never Smoked Cigarettes	690	433	137	34	600	298	170	107	936	226	980	440	12	7	218	44
Current Cigarette Smoker	137	99	393	176	165	75	30	21	357	112	178	73	3	1	150	42
Former Cigarette Smoker	825	559	482	212	625	296	115	80	1174	320	681	282	10	7	533	118

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	<i>Prostate Selected by IMS</i>	<i>Prostate Selected by IMS</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	1652	100.0	1091	100.0	956	100.0	700	100.0	700	100.0	1091	100.0
<i>Cancer Has Advanced Stage/Gleason</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Not Advanced</i>	733	44.4	483	44.3	381	39.9	244	34.9	244	34.9	483	44.3
<i>Somewhat Advanced (Gleason 7)</i>	411	24.9	284	26.0	262	27.4	204	29.1	204	29.1	284	26.0
<i>Advanced (Gleason 8,9,10, or Stage III,I</i>	508	30.8	324	29.7	313	32.7	252	36.0	252	36.0	324	29.7
<i>Gleason Score</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	6	0.4	6	0.5	6	0.6	4	0.6	4	0.6	6	0.5
<i>2</i>	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>3</i>	6	0.4	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>4</i>	32	1.9	17	1.6	10	1.0	5	0.7	5	0.7	17	1.6
<i>5</i>	186	11.3	101	9.3	86	9.0	62	8.9	62	8.9	101	9.3
<i>6</i>	621	37.6	430	39.4	348	36.4	234	33.4	234	33.4	430	39.4
<i>7</i>	601	36.4	405	37.1	380	39.7	293	41.9	293	41.9	405	37.1
<i>8</i>	106	6.4	76	7.0	72	7.5	62	8.9	62	8.9	76	7.0
<i>9</i>	85	5.1	50	4.6	48	5.0	36	5.1	36	5.1	50	4.6
<i>10</i>	4	0.2	4	0.4	4	0.4	3	0.4	3	0.4	4	0.4
<i>Not Available</i>	3	0.2	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1
<i>Prostatectomy Gleason Score</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	6	0.4	6	0.5	6	0.6	4	0.6	4	0.6	6	0.5
<i>2</i>	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>3</i>	6	0.4	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>4</i>	32	1.9	17	1.6	10	1.0	5	0.7	5	0.7	17	1.6
<i>5</i>	182	11.0	99	9.1	84	8.8	60	8.6	60	8.6	99	9.1
<i>6</i>	612	37.0	428	39.2	348	36.4	234	33.4	234	33.4	428	39.2
<i>7</i>	595	36.0	403	36.9	379	39.6	292	41.7	292	41.7	403	36.9
<i>8</i>	105	6.4	76	7.0	72	7.5	62	8.9	62	8.9	76	7.0
<i>9</i>	85	5.1	50	4.6	48	5.0	36	5.1	36	5.1	50	4.6
<i>10</i>	4	0.2	4	0.4	4	0.4	3	0.4	3	0.4	4	0.4
<i>Not Available</i>	23	1.4	7	0.6	4	0.4	3	0.4	3	0.4	7	0.6
<i>Prostate Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Stage II</i>	1220	73.8	823	75.4	696	72.8	487	69.6	487	69.6	823	75.4

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	<i>Prostate Selected by IMS</i>	<i>Prostate Selected by IMS</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>Stage III</i>	378	22.9	231	21.2	223	23.3	184	26.3	184	26.3	231	21.2
<i>Stage IV</i>	53	3.2	37	3.4	37	3.9	29	4.1	29	4.1	37	3.4
<i>Prostate Pathologic Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	40	2.4	29	2.7	24	2.5	16	2.3	16	2.3	29	2.7
<i>Stage II</i>	1182	71.5	795	72.9	673	70.4	471	67.3	471	67.3	795	72.9
<i>Stage III</i>	377	22.8	230	21.1	222	23.2	184	26.3	184	26.3	230	21.1
<i>Stage IV</i>	53	3.2	37	3.4	37	3.9	29	4.1	29	4.1	37	3.4
<i>Prostate Cancer Histopathologic Type</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Adenocarcinoma, NOS</i>	1462	88.5	972	89.1	856	89.5	627	89.6	627	89.6	972	89.1
<i>Adenocarcinoma, Acinar</i>	183	11.1	115	10.5	96	10.0	69	9.9	69	9.9	115	10.5
<i>Adenocarcinoma, Mucinous</i>	5	0.3	3	0.3	3	0.3	3	0.4	3	0.4	3	0.3
<i>Adenocarcinoma, Ductal</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Carcinoma, NOS</i>	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>Prostate Stage T Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>T0</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>T1a</i>	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>T1b</i>	1	0.1	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1
<i>T1c</i>	19	1.2	12	1.1	10	1.0	6	0.9	6	0.9	12	1.1
<i>T2</i>	47	2.8	22	2.0	14	1.5	9	1.3	9	1.3	22	2.0
<i>T2a</i>	296	17.9	189	17.3	140	14.6	87	12.4	87	12.4	189	17.3
<i>T2b</i>	682	41.3	504	46.2	446	46.7	319	45.6	319	45.6	504	46.2
<i>T2c</i>	182	11.0	99	9.1	89	9.3	70	10.0	70	10.0	99	9.1
<i>T3</i>	25	1.5	15	1.4	15	1.6	12	1.7	12	1.7	15	1.4
<i>T3a</i>	234	14.2	147	13.5	144	15.1	124	17.7	124	17.7	147	13.5
<i>T3b</i>	109	6.6	74	6.8	72	7.5	52	7.4	52	7.4	74	6.8
<i>T3c</i>	33	2.0	14	1.3	11	1.2	10	1.4	10	1.4	14	1.3
<i>T4</i>	17	1.0	11	1.0	11	1.2	8	1.1	8	1.1	11	1.0
<i>T4a</i>	5	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Prostate Pathologic Stage T Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	30	1.8	22	2.0	18	1.9	11	1.6	11	1.6	22	2.0
<i>T0</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>T1c</i>	3	0.2	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	<i>Prostate Selected by IMS</i>	<i>Prostate Selected by IMS</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>T2</i>	46	2.8	22	2.0	14	1.5	9	1.3	9	1.3	22	2.0
<i>T2a</i>	291	17.6	183	16.8	135	14.1	83	11.9	83	11.9	183	16.8
<i>T2b</i>	676	40.9	501	45.9	444	46.4	317	45.3	317	45.3	501	45.9
<i>T2c</i>	182	11.0	99	9.1	89	9.3	70	10.0	70	10.0	99	9.1
<i>T3</i>	25	1.5	15	1.4	15	1.6	12	1.7	12	1.7	15	1.4
<i>T3a</i>	234	14.2	147	13.5	144	15.1	124	17.7	124	17.7	147	13.5
<i>T3b</i>	108	6.5	73	6.7	71	7.4	52	7.4	52	7.4	73	6.7
<i>T3c</i>	33	2.0	14	1.3	11	1.2	10	1.4	10	1.4	14	1.3
<i>T4</i>	17	1.0	11	1.0	11	1.2	8	1.1	8	1.1	11	1.0
<i>T4a</i>	5	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>TX</i>	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>Prostate Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	2	0.1	2	0.2	2	0.2	1	0.1	1	0.1	2	0.2
<i>N0</i>	1538	93.1	1022	93.7	892	93.3	657	93.9	657	93.9	1022	93.7
<i>N1</i>	28	1.7	22	2.0	22	2.3	17	2.4	17	2.4	22	2.0
<i>N2</i>	3	0.2	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>NX</i>	81	4.9	43	3.9	38	4.0	23	3.3	23	3.3	43	3.9
<i>Prostate Pathologic Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	34	2.1	26	2.4	21	2.2	14	2.0	14	2.0	26	2.4
<i>N0</i>	1413	85.5	943	86.4	821	85.9	610	87.1	610	87.1	943	86.4
<i>N1</i>	28	1.7	22	2.0	22	2.3	17	2.4	17	2.4	22	2.0
<i>N2</i>	3	0.2	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>NX</i>	174	10.5	98	9.0	90	9.4	57	8.1	57	8.1	98	9.0
<i>Prostate Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	1	0.1	1	0.1	1	0.1	0	0.0	0	0.0	1	0.1
<i>M0</i>	1494	90.4	997	91.4	876	91.6	649	92.7	649	92.7	997	91.4
<i>M1b</i>	2	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>MX</i>	155	9.4	92	8.4	78	8.2	50	7.1	50	7.1	92	8.4
<i>Prostate Pathologic Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	30	1.8	22	2.0	18	1.9	11	1.6	11	1.6	22	2.0
<i>M0</i>	1404	85.0	942	86.3	830	86.8	619	88.4	619	88.4	942	86.3

Table 2.5.1: Prostate Tissue Availability by Prostate Cancer Characteristics

	<i>Prostate Selected by IMS</i>	<i>Prostate Selected by IMS</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With TMA Tumor Cores</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores and Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>	<i>Prostate With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>M1b</i>	2	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>MX</i>	216	13.1	126	11.5	107	11.2	69	9.9	69	9.9	126	11.5

Table 2.5.2: Lung Tissue Availability by Lung Cancer Characteristics

	<i>Lung Selected by IMS</i>	<i>Lung Selected by IMS</i>	<i>Lung With TMA Cores</i>	<i>Lung With TMA Cores</i>	<i>Lung With TMA Tumor Cores</i>	<i>Lung With TMA Tumor Cores</i>	<i>Lung With Tumor DNA</i>	<i>Lung With Tumor DNA</i>	<i>Lung With TMA Cores and Tumor DNA</i>	<i>Lung With TMA Cores and Tumor DNA</i>	<i>Lung With TMA Cores or Tumor DNA</i>	<i>Lung With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	1030	100.0	434	100.0	434	100.0	433	100.0	433	100.0	434	100.0
<i>Lung Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Stage I</i>	5	0.5	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
<i>Stage IA</i>	287	27.9	157	36.2	157	36.2	157	36.3	157	36.3	157	36.2
<i>Stage IB</i>	211	20.5	122	28.1	122	28.1	122	28.2	122	28.2	122	28.1
<i>Stage II</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Stage IIA</i>	25	2.4	16	3.7	16	3.7	16	3.7	16	3.7	16	3.7
<i>Stage IIB</i>	74	7.2	38	8.8	38	8.8	38	8.8	38	8.8	38	8.8
<i>Stage IIIA</i>	86	8.3	39	9.0	39	9.0	38	8.8	38	8.8	39	9.0
<i>Stage IIIB</i>	79	7.7	23	5.3	23	5.3	23	5.3	23	5.3	23	5.3
<i>Stage IV</i>	190	18.4	30	6.9	30	6.9	30	6.9	30	6.9	30	6.9
<i>Small cell</i>	72	7.0	8	1.8	8	1.8	8	1.8	8	1.8	8	1.8
<i>Lung Pathologic Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	352	34.2	56	12.9	56	12.9	55	12.7	55	12.7	56	12.9
<i>Stage IA</i>	249	24.2	137	31.6	137	31.6	137	31.6	137	31.6	137	31.6
<i>Stage IB</i>	190	18.4	111	25.6	111	25.6	111	25.6	111	25.6	111	25.6
<i>Stage IIA</i>	23	2.2	16	3.7	16	3.7	16	3.7	16	3.7	16	3.7
<i>Stage IIB</i>	66	6.4	33	7.6	33	7.6	33	7.6	33	7.6	33	7.6
<i>Stage IIIA</i>	54	5.2	35	8.1	35	8.1	35	8.1	35	8.1	35	8.1
<i>Stage IIIB</i>	32	3.1	20	4.6	20	4.6	20	4.6	20	4.6	20	4.6
<i>Stage IV</i>	63	6.1	25	5.8	25	5.8	25	5.8	25	5.8	25	5.8
<i>Occult Carcinoma</i>	1	0.1	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
<i>Lung Cancer Grade (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Well differentiated; Grade I</i>	160	15.5	51	11.8	51	11.8	51	11.8	51	11.8	51	11.8
<i>Moderately differentiated; Grade II</i>	292	28.3	162	37.3	162	37.3	162	37.4	162	37.4	162	37.3
<i>Poorly differentiated; Grade III</i>	351	34.1	161	37.1	161	37.1	161	37.2	161	37.2	161	37.1
<i>Undifferentiated; Grade IV</i>	76	7.4	30	6.9	30	6.9	30	6.9	30	6.9	30	6.9
<i>T cell; T precursor</i>	2	0.2	1	0.2	1	0.2	1	0.2	1	0.2	1	0.2
<i>Unknown</i>	149	14.5	29	6.7	29	6.7	28	6.5	28	6.5	29	6.7
<i>Lung Cancer Histopathologic Type</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Squamous Cell Carcinoma</i>	228	22.1	115	26.5	115	26.5	115	26.6	115	26.6	115	26.5
<i>Spindle Cell Carcinoma</i>	5	0.5	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7

Table 2.5.2: Lung Tissue Availability by Lung Cancer Characteristics

	<i>Lung Selected by IMS</i>	<i>Lung Selected by IMS</i>	<i>Lung With TMA Cores</i>	<i>Lung With TMA Cores</i>	<i>Lung With TMA Tumor Cores</i>	<i>Lung With TMA Tumor Cores</i>	<i>Lung With Tumor DNA</i>	<i>Lung With Tumor DNA</i>	<i>Lung With TMA Cores and Tumor DNA</i>	<i>Lung With TMA Cores and Tumor DNA</i>	<i>Lung With TMA Cores or Tumor DNA</i>	<i>Lung With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>Missing data</i>	2	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>N0</i>	622	60.4	319	73.5	319	73.5	319	73.7	319	73.7	319	73.5
<i>N1</i>	127	12.3	57	13.1	57	13.1	57	13.2	57	13.2	57	13.1
<i>N2</i>	186	18.1	50	11.5	50	11.5	49	11.3	49	11.3	50	11.5
<i>N3</i>	56	5.4	5	1.2	5	1.2	5	1.2	5	1.2	5	1.2
<i>NX</i>	37	3.6	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7
<i>Lung Pathologic Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	265	25.7	21	4.8	21	4.8	21	4.8	21	4.8	21	4.8
<i>N0</i>	544	52.8	297	68.4	297	68.4	297	68.6	297	68.6	297	68.4
<i>N1</i>	102	9.9	56	12.9	56	12.9	55	12.7	55	12.7	56	12.9
<i>N2</i>	72	7.0	40	9.2	40	9.2	40	9.2	40	9.2	40	9.2
<i>N3</i>	7	0.7	3	0.7	3	0.7	3	0.7	3	0.7	3	0.7
<i>NX</i>	40	3.9	17	3.9	17	3.9	17	3.9	17	3.9	17	3.9
<i>Lung Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>M0</i>	773	75.0	393	90.6	393	90.6	392	90.5	392	90.5	393	90.6
<i>M1</i>	235	22.8	32	7.4	32	7.4	32	7.4	32	7.4	32	7.4
<i>MX</i>	22	2.1	9	2.1	9	2.1	9	2.1	9	2.1	9	2.1
<i>Lung Pathologic Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	264	25.6	21	4.8	21	4.8	21	4.8	21	4.8	21	4.8
<i>M0</i>	632	61.4	362	83.4	362	83.4	361	83.4	361	83.4	362	83.4
<i>M1</i>	63	6.1	25	5.8	25	5.8	25	5.8	25	5.8	25	5.8
<i>MX</i>	71	6.9	26	6.0	26	6.0	26	6.0	26	6.0	26	6.0

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	<i>Colorectal Selected by IMS</i>	<i>Colorectal Selected by IMS</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	1398	100.0	673	100.0	662	100.0	418	100.0	417	100.0	674	100.0
<i>Colorectal Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>Stage I</i>	502	35.9	219	32.5	214	32.3	129	30.9	129	30.9	219	32.5
<i>Stage II</i>	350	25.0	183	27.2	181	27.3	114	27.3	114	27.3	183	27.2
<i>Stage III</i>	329	23.5	204	30.3	201	30.4	134	32.1	133	31.9	205	30.4
<i>Stage IV</i>	162	11.6	65	9.7	64	9.7	41	9.8	41	9.8	65	9.6
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Colorectal Pathologic Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	232	16.6	75	11.1	71	10.7	48	11.5	48	11.5	75	11.1
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>Stage I</i>	384	27.5	188	27.9	184	27.8	112	26.8	112	26.9	188	27.9
<i>Stage II</i>	307	22.0	164	24.4	164	24.8	100	23.9	100	24.0	164	24.3
<i>Stage III</i>	281	20.1	183	27.2	181	27.3	120	28.7	119	28.5	184	27.3
<i>Stage IV</i>	142	10.2	61	9.1	60	9.1	38	9.1	38	9.1	61	9.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Colon Cancer Grade (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>Well Differentiated (Grade I)</i>	145	10.4	66	9.8	65	9.8	42	10.0	42	10.1	66	9.8
<i>Moderately Differentiated (Grade II)</i>	875	62.6	452	67.2	445	67.2	275	65.8	274	65.7	453	67.2
<i>Poorly Differentiated (Grade III)</i>	184	13.2	90	13.4	90	13.6	63	15.1	63	15.1	90	13.4
<i>Undifferentiated (Grade IV)</i>	12	0.9	3	0.4	3	0.5	2	0.5	2	0.5	3	0.4
<i>Unknown</i>	162	11.6	60	8.9	57	8.6	36	8.6	36	8.6	60	8.9
<i>Colorectal Cancer Histopathologic Type</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>Adenocarcinoma NOS</i>	1185	84.8	595	88.4	584	88.2	374	89.5	373	89.4	596	88.4
<i>Mucinous Adenocarcinoma</i>	134	9.6	69	10.3	69	10.4	38	9.1	38	9.1	69	10.2
<i>Signet Ring Cell Carcinoma</i>	14	1.0	5	0.7	5	0.8	4	1.0	4	1.0	5	0.7
<i>Squamous Cell Carcinoma</i>	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Undifferentiated Carcinoma</i>	2	0.1	1	0.1	1	0.2	1	0.2	1	0.2	1	0.1
<i>Carcinoma NOS</i>	7	0.5	1	0.1	1	0.2	1	0.2	1	0.2	1	0.1
<i>Carcinoma, NOS</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	<i>Colorectal Selected by IMS</i>	<i>Colorectal Selected by IMS</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>Adenocarcinoid</i>	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Carcinoid/Neuroendocrine Carcinoma</i>	31	2.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Colorectal Stage T Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	10	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>T1</i>	280	20.0	96	14.3	91	13.7	50	12.0	49	11.8	97	14.4
<i>T2</i>	274	19.6	153	22.7	152	23.0	99	23.7	99	23.7	153	22.7
<i>T3</i>	677	48.4	380	56.5	375	56.6	238	56.9	238	57.1	380	56.4
<i>T4</i>	91	6.5	41	6.1	41	6.2	30	7.2	30	7.2	41	6.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>TX</i>	14	1.0	1	0.1	1	0.2	1	0.2	1	0.2	1	0.1
<i>Colorectal Pathologic Stage T Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	85	6.1	11	1.6	9	1.4	7	1.7	7	1.7	11	1.6
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>T1</i>	255	18.2	91	13.5	86	13.0	49	11.7	48	11.5	92	13.6
<i>T2</i>	258	18.5	152	22.6	150	22.7	97	23.2	97	23.3	152	22.6
<i>T3</i>	659	47.1	375	55.7	373	56.3	234	56.0	234	56.1	375	55.6
<i>T4</i>	83	5.9	41	6.1	41	6.2	30	7.2	30	7.2	41	6.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>TX</i>	6	0.4	1	0.1	1	0.2	1	0.2	1	0.2	1	0.1
<i>Colorectal Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	7	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>N0</i>	842	60.2	405	60.2	399	60.3	249	59.6	249	59.7	405	60.1
<i>N1</i>	283	20.2	169	25.1	164	24.8	106	25.4	105	25.2	170	25.2
<i>N2</i>	168	12.0	88	13.1	88	13.3	59	14.1	59	14.1	88	13.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>NX</i>	46	3.3	9	1.3	9	1.4	4	1.0	4	1.0	9	1.3
<i>Colorectal Pathologic Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	72	5.2	10	1.5	9	1.4	5	1.2	5	1.2	10	1.5
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
<i>N0</i>	780	55.8	391	58.1	385	58.2	244	58.4	244	58.5	391	58.0
<i>N1</i>	274	19.6	168	25.0	164	24.8	105	25.1	104	24.9	169	25.1

Table 2.5.3: Colorectal Tissue Availability by Colorectal Cancer Characteristics

	<i>Colorectal Selected by IMS</i>	<i>Colorectal Selected by IMS</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With TMA Tumor Cores</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores and Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>	<i>Colorectal With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
N2	167	11.9	88	13.1	88	13.3	59	14.1	59	14.1	88	13.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NX	53	3.8	14	2.1	14	2.1	5	1.2	5	1.2	14	2.1
<i>Colorectal Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	6	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
M0	1095	78.3	568	84.4	559	84.4	351	84.0	350	83.9	569	84.4
M1	161	11.5	65	9.7	64	9.7	41	9.8	41	9.8	65	9.6
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MX	84	6.0	38	5.6	37	5.6	26	6.2	26	6.2	38	5.6
<i>Colorectal Pathologic Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing data</i>	68	4.9	9	1.3	8	1.2	5	1.2	5	1.2	9	1.3
<i>Not Applicable</i>	20	1.4	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
M0	1007	72.0	544	80.8	537	81.1	336	80.4	335	80.3	545	80.9
M1	142	10.2	61	9.1	60	9.1	38	9.1	38	9.1	61	9.1
<i>Carcinoid, cannot be assessed</i>	32	2.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MX	129	9.2	57	8.5	55	8.3	39	9.3	39	9.4	57	8.5
<i>Colorectal Tumor Side/Location</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Not Applicable</i>	18	1.3	2	0.3	2	0.3	0	0.0	0	0.0	2	0.3
Distal	651	46.6	278	41.3	272	41.1	160	38.3	159	38.1	279	41.4
Proximal	728	52.1	393	58.4	388	58.6	258	61.7	258	61.9	393	58.3
Unclear	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	Ovarian Selected by IMS	Ovarian Selected by IMS	Ovarian With TMA Cores	Ovarian With TMA Cores	Ovarian With TMA Tumor Cores	Ovarian With TMA Tumor Cores	Ovarian With Tumor DNA	Ovarian With Tumor DNA	Ovarian With TMA Cores and Tumor DNA	Ovarian With TMA Cores and Tumor DNA	Ovarian With TMA Cores or Tumor DNA	Ovarian With TMA Cores or Tumor DNA
	N	%	N	%	N	%	N	%	N	%	N	%
<i>All</i>	321	100.0	212	100.0	211	100.0	211	100.0	211	100.0	212	100.0
<i>Ovarian Cancer Type</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Invasive Ovarian</i>	245	76.3	166	78.3	165	78.2	165	78.2	165	78.2	166	78.3
<i>Primary Peritoneal</i>	40	12.5	25	11.8	25	11.8	25	11.8	25	11.8	25	11.8
<i>Fallopian Tube</i>	13	4.0	8	3.8	8	3.8	8	3.8	8	3.8	8	3.8
<i>Ovarian Low Malignancy Potential Tumor</i>	21	6.5	12	5.7	12	5.7	12	5.7	12	5.7	12	5.7
<i>Peritoneal Low Malignancy Potential Tumor</i>	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Fallopian Tube Low Malignancy Potential</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Ovarian Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	6	1.9	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Stage I</i>	3	0.9	2	0.9	2	0.9	2	0.9	2	0.9	2	0.9
<i>Stage IA</i>	35	10.9	20	9.4	20	9.5	19	9.0	19	9.0	20	9.4
<i>Stage IB</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>Stage IC</i>	22	6.9	18	8.5	18	8.5	18	8.5	18	8.5	18	8.5
<i>Stage II</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Stage IIA</i>	3	0.9	2	0.9	2	0.9	2	0.9	2	0.9	2	0.9
<i>Stage IIB</i>	10	3.1	7	3.3	7	3.3	7	3.3	7	3.3	7	3.3
<i>Stage IIC</i>	14	4.4	6	2.8	6	2.8	6	2.8	6	2.8	6	2.8
<i>Stage III</i>	6	1.9	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>Stage IIIA</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>Stage IIIB</i>	18	5.6	12	5.7	12	5.7	12	5.7	12	5.7	12	5.7
<i>Stage IIIC</i>	130	40.5	89	42.0	89	42.2	89	42.2	89	42.2	89	42.0
<i>Stage IV</i>	56	17.4	34	16.0	33	15.6	34	16.1	34	16.1	34	16.0
<i>Ovarian Pathologic Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	111	34.6	77	36.3	77	36.5	76	36.0	76	36.0	77	36.3
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Stage I</i>	2	0.6	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Stage IA</i>	26	8.1	13	6.1	13	6.2	13	6.2	13	6.2	13	6.1
<i>Stage IB</i>	5	1.6	3	1.4	3	1.4	3	1.4	3	1.4	3	1.4
<i>Stage IC</i>	16	5.0	13	6.1	13	6.2	13	6.2	13	6.2	13	6.1
<i>Stage IIA</i>	3	0.9	2	0.9	2	0.9	2	0.9	2	0.9	2	0.9

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	Ovarian Selected by IMS	Ovarian Selected by IMS	Ovarian With TMA Cores	Ovarian With TMA Cores	Ovarian With TMA Tumor Cores	Ovarian With TMA Tumor Cores	Ovarian With Tumor DNA	Ovarian With Tumor DNA	Ovarian With TMA Cores and Tumor DNA	Ovarian With TMA Cores and Tumor DNA	Ovarian With TMA Cores or Tumor DNA	Ovarian With TMA Cores or Tumor DNA
	N	%	N	%	N	%	N	%	N	%	N	%
<i>Missing</i>	8	2.5	6	2.8	6	2.8	6	2.8	6	2.8	6	2.8
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T0</i>	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>T1</i>	2	0.6	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T1a</i>	35	10.9	20	9.4	20	9.5	19	9.0	19	9.0	20	9.4
<i>T1b</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T1c</i>	25	7.8	20	9.4	20	9.5	20	9.5	20	9.5	20	9.4
<i>T2</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T2a</i>	4	1.2	2	0.9	2	0.9	2	0.9	2	0.9	2	0.9
<i>T2b</i>	14	4.4	9	4.2	9	4.3	9	4.3	9	4.3	9	4.2
<i>T2c</i>	18	5.6	10	4.7	10	4.7	10	4.7	10	4.7	10	4.7
<i>T3</i>	7	2.2	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T3a</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T3b</i>	29	9.0	22	10.4	22	10.4	22	10.4	22	10.4	22	10.4
<i>T3c</i>	159	49.5	104	49.1	103	48.8	104	49.3	104	49.3	104	49.1
<i>TX</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Ovarian Pathologic Stage T Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	11	3.4	6	2.8	6	2.8	6	2.8	6	2.8	6	2.8
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T0</i>	1	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>T1</i>	2	0.6	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T1a</i>	35	10.9	20	9.4	20	9.5	19	9.0	19	9.0	20	9.4
<i>T1b</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T1c</i>	25	7.8	20	9.4	20	9.5	20	9.5	20	9.5	20	9.4
<i>T2</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>T2a</i>	3	0.9	2	0.9	2	0.9	2	0.9	2	0.9	2	0.9
<i>T2b</i>	14	4.4	9	4.2	9	4.3	9	4.3	9	4.3	9	4.2
<i>T2c</i>	18	5.6	10	4.7	10	4.7	10	4.7	10	4.7	10	4.7
<i>T3</i>	6	1.9	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T3a</i>	8	2.5	5	2.4	5	2.4	5	2.4	5	2.4	5	2.4
<i>T3b</i>	29	9.0	22	10.4	22	10.4	22	10.4	22	10.4	22	10.4
<i>T3c</i>	158	49.2	104	49.1	103	48.8	104	49.3	104	49.3	104	49.1

Table 2.5.4: Ovary Tissue Availability by Ovarian Cancer Characteristics

	<i>Ovarian Selected by IMS</i>	<i>Ovarian Selected by IMS</i>	<i>Ovarian With TMA Cores</i>	<i>Ovarian With TMA Cores</i>	<i>Ovarian With TMA Tumor Cores</i>	<i>Ovarian With TMA Tumor Cores</i>	<i>Ovarian With Tumor DNA</i>	<i>Ovarian With Tumor DNA</i>	<i>Ovarian With TMA Cores and Tumor DNA</i>	<i>Ovarian With TMA Cores and Tumor DNA</i>	<i>Ovarian With TMA Cores or Tumor DNA</i>	<i>Ovarian With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>TX</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>Ovarian Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	12	3.7	10	4.7	10	4.7	10	4.7	10	4.7	10	4.7
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>N0</i>	153	47.7	98	46.2	97	46.0	98	46.4	98	46.4	98	46.2
<i>N1</i>	48	15.0	33	15.6	33	15.6	33	15.6	33	15.6	33	15.6
<i>NX</i>	107	33.3	70	33.0	70	33.2	69	32.7	69	32.7	70	33.0
<i>Ovarian Pathologic Stage N Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	15	4.7	10	4.7	10	4.7	10	4.7	10	4.7	10	4.7
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>N0</i>	141	43.9	89	42.0	88	41.7	89	42.2	89	42.2	89	42.0
<i>N1</i>	46	14.3	32	15.1	32	15.2	32	15.2	32	15.2	32	15.1
<i>NX</i>	118	36.8	80	37.7	80	37.9	79	37.4	79	37.4	80	37.7
<i>Ovarian Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	9	2.8	7	3.3	7	3.3	7	3.3	7	3.3	7	3.3
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>M0</i>	220	68.5	149	70.3	149	70.6	148	70.1	148	70.1	149	70.3
<i>M1</i>	53	16.5	32	15.1	31	14.7	32	15.2	32	15.2	32	15.1
<i>MX</i>	38	11.8	23	10.8	23	10.9	23	10.9	23	10.9	23	10.8
<i>Ovarian Pathologic Stage M Component</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	12	3.7	7	3.3	7	3.3	7	3.3	7	3.3	7	3.3
<i>Not Applicable</i>	1	0.3	1	0.5	1	0.5	1	0.5	1	0.5	1	0.5
<i>M0</i>	216	67.3	147	69.3	147	69.7	146	69.2	146	69.2	147	69.3
<i>M1</i>	51	15.9	31	14.6	30	14.2	31	14.7	31	14.7	31	14.6
<i>MX</i>	41	12.8	26	12.3	26	12.3	26	12.3	26	12.3	26	12.3

Table 2.5.5: Adenoma Tissue Availability by Adenoma Characteristics at Time of Selection

	<i>Adenoma Selected by IMS</i>	<i>Adenoma Selected by IMS</i>	<i>Adenoma With TMA Cores</i>	<i>Adenoma With TMA Cores</i>	<i>Adenoma With TMA Tumor Cores</i>	<i>Adenoma With TMA Tumor Cores</i>	<i>Adenoma With Tumor DNA</i>	<i>Adenoma With Tumor DNA</i>	<i>Adenoma With TMA Cores and Tumor DNA</i>	<i>Adenoma With TMA Cores and Tumor DNA</i>	<i>Adenoma With TMA Cores or Tumor DNA</i>	<i>Adenoma With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	2468	100.0	658	100.0	658	100.0	197	100.0	197	100.0	658	100.0
<i>Adenoma Found Following Positive T0 Screen</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>No Form</i>	624	25.3	173	26.3	173	26.3	53	26.9	53	26.9	173	26.3
<i>No</i>	111	4.5	18	2.7	18	2.7	1	0.5	1	0.5	18	2.7
<i>Yes</i>	1693	68.6	455	69.1	455	69.1	142	72.1	142	72.1	455	69.1
<i>Unknown</i>	16	0.6	7	1.1	7	1.1	1	0.5	1	0.5	7	1.1
<i>No Known Endoscopy</i>	24	1.0	5	0.8	5	0.8	0	0.0	0	0.0	5	0.8
<i>Has an incident adenoma</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Control Arm</i>	96	3.9	36	5.5	36	5.5	15	7.6	15	7.6	36	5.5
<i>Not in Incident Adenoma Cohort</i>	1918	77.7	495	75.2	495	75.2	147	74.6	147	74.6	495	75.2
<i>No Adenoma</i>	6	0.2	1	0.2	1	0.2	0	0.0	0	0.0	1	0.2
<i>Has Adenoma</i>	448	18.2	126	19.1	126	19.1	35	17.8	35	17.8	126	19.1
<i>Has a recurrent adenoma</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Control</i>	96	3.9	36	5.5	36	5.5	15	7.6	15	7.6	36	5.5
<i>Not in recurrent adenoma cohort</i>	1438	58.3	383	58.2	383	58.2	117	59.4	117	59.4	383	58.2
<i>No recurrent adenoma</i>	319	12.9	70	10.6	70	10.6	22	11.2	22	11.2	70	10.6
<i>Has a recurrent adenoma</i>	615	24.9	169	25.7	169	25.7	43	21.8	43	21.8	169	25.7
<i>Size of Largest Adenoma</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>No tissue materials</i>	1599	64.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Missing</i>	5	0.2	4	0.6	4	0.6	0	0.0	0	0.0	4	0.6
<i>Small</i>	289	11.7	170	25.8	170	25.8	36	18.3	36	18.3	170	25.8
<i>Large</i>	575	23.3	484	73.6	484	73.6	161	81.7	161	81.7	484	73.6
<i>Source of Adenoma(s)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>No tissue materials</i>	1599	64.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>CANCER</i>	62	2.5	44	6.7	44	6.7	16	8.1	16	8.1	44	6.7
<i>CANCER, T00</i>	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>SCU</i>	42	1.7	22	3.3	22	3.3	4	2.0	4	2.0	22	3.3
<i>SCU, T00</i>	38	1.5	31	4.7	31	4.7	7	3.6	7	3.6	31	4.7
<i>SCU, T00, T05</i>	1	0.0	1	0.2	1	0.2	1	0.5	1	0.5	1	0.2
<i>SCU, T03</i>	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>T00</i>	493	20.0	393	59.7	393	59.7	129	65.5	129	65.5	393	59.7
<i>T00, T03</i>	2	0.1	2	0.3	2	0.3	1	0.5	1	0.5	2	0.3

Table 2.5.5: Adenoma Tissue Availability by Adenoma Characteristics at Time of Selection

	<i>Adenoma Selected by IMS</i>	<i>Adenoma Selected by IMS</i>	<i>Adenoma With TMA Cores</i>	<i>Adenoma With TMA Cores</i>	<i>Adenoma With TMA Tumor Cores</i>	<i>Adenoma With TMA Tumor Cores</i>	<i>Adenoma With Tumor DNA</i>	<i>Adenoma With Tumor DNA</i>	<i>Adenoma With TMA Cores and Tumor DNA</i>	<i>Adenoma With TMA Cores and Tumor DNA</i>	<i>Adenoma With TMA Cores or Tumor DNA</i>	<i>Adenoma With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>T00, T05</i>	4	0.2	3	0.5	3	0.5	1	0.5	1	0.5	3	0.5
<i>T03</i>	54	2.2	35	5.3	35	5.3	6	3.0	6	3.0	35	5.3
<i>T05</i>	171	6.9	127	19.3	127	19.3	32	16.2	32	16.2	127	19.3

Table 2.5.6: Female-Breast Tissue Availability by Breast Cancer Characteristics

	<i>Breast Selected by IMS</i>	<i>Breast Selected by IMS</i>	<i>Breast With TMA Cores</i>	<i>Breast With TMA Cores</i>	<i>Breast With TMA Tumor Cores</i>	<i>Breast With TMA Tumor Cores</i>	<i>Breast With Tumor DNA</i>	<i>Breast With Tumor DNA</i>	<i>Breast With TMA Cores and Tumor DNA</i>	<i>Breast With TMA Cores and Tumor DNA</i>	<i>Breast With TMA Cores or Tumor DNA</i>	<i>Breast With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	1852	100.0	801	100.0	801	100.0	770	100.0	769	100.0	802	100.0
<i>Breast Cancer Type</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Lobular</i>	200	10.8	100	12.5	100	12.5	95	12.3	95	12.4	100	12.5
<i>Tubular</i>	48	2.6	15	1.9	15	1.9	13	1.7	13	1.7	15	1.9
<i>Ductal, NOS</i>	1344	72.6	599	74.8	599	74.8	576	74.8	576	74.9	599	74.7
<i>Other</i>	260	14.0	87	10.9	87	10.9	86	11.2	85	11.1	88	11.0
<i>Breast Cancer Grade</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Well Differentiated; Grade I</i>	313	16.9	156	19.5	156	19.5	146	19.0	146	19.0	156	19.5
<i>Moderately Differentiated; Grade II</i>	548	29.6	288	36.0	288	36.0	278	36.1	278	36.2	288	35.9
<i>Poorly Differentiated; Grade III</i>	420	22.7	214	26.7	214	26.7	208	27.0	208	27.0	214	26.7
<i>Undifferentiated; Grade IV</i>	6	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Not Determined/Stated/or Applicable</i>	565	30.5	141	17.6	141	17.6	136	17.7	135	17.6	142	17.7
<i>Breast Stage (AJCC 5th Edition)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing Data</i>	3	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>Stage 0</i>	611	33.0	109	13.6	109	13.6	100	13.0	99	12.9	110	13.7
<i>Stage I</i>	722	39.0	378	47.2	378	47.2	359	46.6	359	46.7	378	47.1
<i>Stage IIA</i>	309	16.7	189	23.6	189	23.6	186	24.2	186	24.2	189	23.6
<i>Stage IIB</i>	138	7.5	83	10.4	83	10.4	83	10.8	83	10.8	83	10.3
<i>Stage IIIA</i>	33	1.8	20	2.5	20	2.5	20	2.6	20	2.6	20	2.5
<i>Stage IIIB</i>	27	1.5	15	1.9	15	1.9	15	1.9	15	2.0	15	1.9
<i>Stage IV</i>	9	0.5	7	0.9	7	0.9	7	0.9	7	0.9	7	0.9
<i>Breast Cancer Behavior</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>In Situ</i>	611	33.0	109	13.6	109	13.6	100	13.0	99	12.9	110	13.7
<i>Malignant, Primary Site</i>	1241	67.0	692	86.4	692	86.4	670	87.0	670	87.1	692	86.3
<i>Breast Cancer Tumor Size</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Missing</i>	621	33.5	111	13.9	111	13.9	102	13.2	101	13.1	112	14.0
<i>0 cm to Less Than 2 cm</i>	883	47.7	479	59.8	479	59.8	459	59.6	459	59.7	479	59.7
<i>2 cm to Less Than 5 cm</i>	317	17.1	190	23.7	190	23.7	188	24.4	188	24.4	190	23.7
<i>5 cm or More</i>	31	1.7	21	2.6	21	2.6	21	2.7	21	2.7	21	2.6
<i>Breast Cancer Topography</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Nipple</i>	22	1.2	5	0.6	5	0.6	4	0.5	4	0.5	5	0.6
<i>Central Portion of Breast</i>	137	7.4	48	6.0	48	6.0	45	5.8	45	5.9	48	6.0

Table 2.5.6: Female-Breast Tissue Availability by Breast Cancer Characteristics

	<i>Breast Selected by IMS</i>	<i>Breast Selected by IMS</i>	<i>Breast With TMA Cores</i>	<i>Breast With TMA Cores</i>	<i>Breast With TMA Tumor Cores</i>	<i>Breast With TMA Tumor Cores</i>	<i>Breast With Tumor DNA</i>	<i>Breast With Tumor DNA</i>	<i>Breast With TMA Cores and Tumor DNA</i>	<i>Breast With TMA Cores and Tumor DNA</i>	<i>Breast With TMA Cores or Tumor DNA</i>	<i>Breast With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>Upper Inner Quadrant of Breast</i>	173	9.3	80	10.0	80	10.0	75	9.7	75	9.8	80	10.0
<i>Lower Inner Quadrant of Breast</i>	112	6.0	52	6.5	52	6.5	51	6.6	51	6.6	52	6.5
<i>Upper Outer Quadrant of Breast</i>	675	36.4	299	37.3	299	37.3	291	37.8	290	37.7	300	37.4
<i>Lower Outer Quadrant of Breast</i>	131	7.1	71	8.9	71	8.9	70	9.1	70	9.1	71	8.9
<i>Axillary Tail of Breast</i>	5	0.3	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Overlapping Lesion of Breast</i>	420	22.7	181	22.6	181	22.6	172	22.3	172	22.4	181	22.6
<i>Breast NOS</i>	177	9.6	63	7.9	63	7.9	60	7.8	60	7.8	63	7.9
<i>Estrogen Receptor Status</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Negative</i>	367	19.8	202	25.2	202	25.2	200	26.0	200	26.0	202	25.2
<i>Equivocal - Positive Cells Within Range</i>	22	1.2	16	2.0	16	2.0	16	2.1	16	2.1	16	2.0
<i>Positive</i>	1079	58.3	494	61.7	494	61.7	471	61.2	471	61.2	494	61.6
<i>Not Available</i>	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>Ordered, No Results</i>	10	0.5	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Not Ordered</i>	373	20.1	86	10.7	86	10.7	80	10.4	79	10.3	87	10.8
<i>Progesterone Receptor Status</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Negative</i>	619	33.4	328	40.9	328	40.9	317	41.2	317	41.2	328	40.9
<i>Equivocal - Positive Cells Within Range</i>	107	5.8	64	8.0	64	8.0	63	8.2	63	8.2	64	8.0
<i>Positive</i>	729	39.4	316	39.5	316	39.5	303	39.4	303	39.4	316	39.4
<i>Indeterminant</i>	4	0.2	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Not Available</i>	2	0.1	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1
<i>Ordered, No Results</i>	11	0.6	2	0.2	2	0.2	2	0.3	2	0.3	2	0.2
<i>Not Ordered</i>	380	20.5	88	11.0	88	11.0	82	10.6	81	10.5	89	11.1
<i>HER2 Summary</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Positive</i>	145	7.8	73	9.1	73	9.1	71	9.2	71	9.2	73	9.1
<i>Equivocal</i>	68	3.7	44	5.5	44	5.5	44	5.7	44	5.7	44	5.5
<i>Negative</i>	699	37.7	386	48.2	386	48.2	369	47.9	369	48.0	386	48.1
<i>Indeterminant</i>	18	1.0	12	1.5	12	1.5	11	1.4	11	1.4	12	1.5
<i>Ordered, No Results</i>	922	49.8	286	35.7	286	35.7	275	35.7	274	35.6	287	35.8

Table 2.5.7: Male-Breast Tissue Availability by Breast Cancer Characteristics

	<i>Male Breast Selected by IMS</i>	<i>Male Breast Selected by IMS</i>	<i>Male Breast With TMA Cores</i>	<i>Male Breast With TMA Cores</i>	<i>Male Breast With TMA Tumor Cores</i>	<i>Male Breast With TMA Tumor Cores</i>	<i>Male Breast With Tumor DNA</i>	<i>Male Breast With Tumor DNA</i>	<i>Male Breast With TMA Cores and Tumor DNA</i>	<i>Male Breast With TMA Cores and Tumor DNA</i>	<i>Male Breast With TMA Cores or Tumor DNA</i>	<i>Male Breast With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	27	100.0	17	100.0	17	100.0	17	100.0	17	100.0	17	100.0
<i>Male Breast Cancer Behavior (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>In Situ</i>	2	7.4	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
<i>Malignant, Primary Site</i>	25	92.6	16	94.1	16	94.1	16	94.1	16	94.1	16	94.1
<i>Male Breast Cancer Grade (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Well Differentiated; Grade I</i>	6	22.2	5	29.4	5	29.4	5	29.4	5	29.4	5	29.4
<i>Moderately Differentiated; Grade II</i>	12	44.4	6	35.3	6	35.3	6	35.3	6	35.3	6	35.3
<i>Poorly Differentiated; Grade III</i>	4	14.8	4	23.5	4	23.5	4	23.5	4	23.5	4	23.5
<i>Not Determined/Stated/Applicable</i>	5	18.5	2	11.8	2	11.8	2	11.8	2	11.8	2	11.8
<i>Male Breast Cancer Morphology (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>8010</i>	1	3.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>8050</i>	1	3.7	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
<i>8201</i>	1	3.7	1	5.9	1	5.9	1	5.9	1	5.9	1	5.9
<i>8500</i>	23	85.2	15	88.2	15	88.2	15	88.2	15	88.2	15	88.2
<i>8504</i>	1	3.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 2.5.8: Bladder Tissue Availability by Bladder Cancer Characteristics

	<i>Bladder Selected by IMS</i>	<i>Bladder Selected by IMS</i>	<i>Bladder With TMA Cores</i>	<i>Bladder With TMA Cores</i>	<i>Bladder With TMA Tumor Cores</i>	<i>Bladder With TMA Tumor Cores</i>	<i>Bladder With Tumor DNA</i>	<i>Bladder With Tumor DNA</i>	<i>Bladder With TMA Cores and Tumor DNA</i>	<i>Bladder With TMA Cores and Tumor DNA</i>	<i>Bladder With TMA Cores or Tumor DNA</i>	<i>Bladder With TMA Cores or Tumor DNA</i>
	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>	<i>N</i>	<i>%</i>
<i>All</i>	901	100.0	200	100.0	200	100.0	158	100.0	155	100.0	203	100.0
<i>Bladder Cancer Behavior (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Uncertain, Borderline, or LMP</i>	4	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
<i>In Situ</i>	259	28.7	45	22.5	45	22.5	31	19.6	30	19.4	46	22.7
<i>Malignant, Primary Site</i>	638	70.8	155	77.5	155	77.5	127	80.4	125	80.6	157	77.3
<i>Bladder Cancer Grade (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>Well Differentiated; Grade I</i>	214	23.8	45	22.5	45	22.5	34	21.5	34	21.9	45	22.2
<i>Moderately Differentiated; Grade II</i>	192	21.3	44	22.0	44	22.0	36	22.8	36	23.2	44	21.7
<i>Poorly Differentiated; Grade III</i>	291	32.3	79	39.5	79	39.5	62	39.2	61	39.4	80	39.4
<i>Undifferentiated; Grade IV</i>	49	5.4	13	6.5	13	6.5	12	7.6	11	7.1	14	6.9
<i>Not Determined/Stated/Applicable</i>	155	17.2	19	9.5	19	9.5	14	8.9	13	8.4	20	9.9
<i>Bladder Cancer Morphology (ICD-O-2)</i>	.	.	.	.	.	.	.	.	.	.	.	.
<i>8010</i>	7	0.8	1	0.5	1	0.5	1	0.6	1	0.6	1	0.5
<i>8020</i>	2	0.2	1	0.5	1	0.5	0	0.0	0	0.0	1	0.5
<i>8050</i>	9	1.0	1	0.5	1	0.5	2	1.3	1	0.6	2	1.0
<i>8120</i>	330	36.6	67	33.5	67	33.5	58	36.7	56	36.1	69	34.0
<i>8130</i>	551	61.2	129	64.5	129	64.5	96	60.8	96	61.9	129	63.5
<i>8980</i>	2	0.2	1	0.5	1	0.5	1	0.6	1	0.6	1	0.5